Liver and Bile Duct Cancer Research
Targeted Treatment for Rare Digestive Tract Cancers May Extend SurvivalPosted: December 7, 2018
In an early-phase trial, dabrafenib plus trametinib shrank tumors in patients with biliary tract cancer and adenocarcinoma of the small intestine whose tumors had a specific mutation in the BRAF gene.
NCI study finds gut microbiome can control antitumor immune function in liverPosted: May 24, 2018
An NCI study in mice that found a connection between gut bacteria and antitumor immune responses in the liver has implications for understanding mechanisms that lead to liver cancer and for potential treatments. The study was published in Science.
Nivolumab Receives Accelerated Approval from FDA for Advanced Liver CancerPosted: October 20, 2017
The FDA has granted accelerated approval to the immunotherapy drug nivolumab (Opdivo®) for patients with advanced liver cancer who have previously been treated with the targeted therapy sorafenib (Nexavar®).
TCGA study of liver cancer reveals potential targets for therapyPosted: June 15, 2017
Only two drugs are FDA-approved for liver cancer. This study of hepatocellular carcinoma found genetic alterations in tumors—including mutations in tumor-suppressing genes and high expression of immune checkpoint genes—that could be targets for drugs that already exist.
Regorafenib Becomes First FDA-Approved Drug for Liver Cancer in Nearly a DecadePosted: May 24, 2017
FDA approved the kinase inhibitor regorafenib for some patients with hepatocellular carcinoma, the most common form of liver cancer.
Investigators discover new gene that affects clearance of hepatitis C virusPosted: January 7, 2013
Scientists have discovered a new human interferon gene, Interferon Lambda 4 (IFNL4), that affects clearance of the hepatitis C virus. They also identified an inherited genetic variant within IFNL4 that predicts how people respond to treatment for hepatitis C infection.